Metastatic breast cancer: Endocrine therapy landscape reshaped

Endocrine therapy (ET) of hormone receptor (HR)-positive and human epidermal growth factor receptor 2-(HER2)-negative metastatic breast cancer (MBC) historically focused on estrogen deprivation and antagonism. The identification of several intracellular pathways promoting resistance to antiestrogen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohamad Adham Salkeni, Samantha June Hall
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2017
Materias:	breast cancer endocrine therapy metastatic Medicine R
Acceso en línea:	https://doaj.org/article/3269b6d99960484c8d2f4b76e075e6f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3269b6d99960484c8d2f4b76e075e6f0
record_format	dspace
spelling	oai:doaj.org-article:3269b6d99960484c8d2f4b76e075e6f02021-12-02T16:24:58ZMetastatic breast cancer: Endocrine therapy landscape reshaped2231-07702249-446410.4103/ajm.AJM_20_17https://doaj.org/article/3269b6d99960484c8d2f4b76e075e6f02017-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/ajm.AJM_20_17https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Endocrine therapy (ET) of hormone receptor (HR)-positive and human epidermal growth factor receptor 2-(HER2)-negative metastatic breast cancer (MBC) historically focused on estrogen deprivation and antagonism. The identification of several intracellular pathways promoting resistance to antiestrogen therapy led to the introduction of novel endocrine drug combinations that reformed treatment schema and expanded therapeutic options. There is no doubt that efforts to overcome or delay resistance to ET are fruiting, particularly with the introduction of cyclin-dependent kinase 4/6 inhibitors such as palbociclib and ribociclib, and mechanistic target of rapamycin inhibitors such as everolimus. Although still considered incurable by currently available treatment modalities, many patients with MBC nowadays enjoy several years of good quality life coupled with decent tumor control. The diversity of therapies and unusual pattern of side effects can be quite perplexing to the treating physician. The sequence of variable agents and management of side effects, in addition to the timing of initiation of cytotoxic chemotherapy, is among the challenges faced by oncologists. In this review, we shed a spotlight on mechanisms of resistance to ET, and provide a review of landmark studies that have recently reshaped the landscape of treatment options for patients with metastatic HR-positive, HER2-negative MBC. A suggested treatment strategy for newly diagnosed patients is also discussed herein.Mohamad Adham SalkeniSamantha June HallThieme Medical and Scientific Publishers Pvt. Ltd.articlebreast cancerendocrine therapymetastaticMedicineRENAvicenna Journal of Medicine, Vol 07, Iss 04, Pp 144-152 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer endocrine therapy metastatic Medicine R
spellingShingle	breast cancer endocrine therapy metastatic Medicine R Mohamad Adham Salkeni Samantha June Hall Metastatic breast cancer: Endocrine therapy landscape reshaped
description	Endocrine therapy (ET) of hormone receptor (HR)-positive and human epidermal growth factor receptor 2-(HER2)-negative metastatic breast cancer (MBC) historically focused on estrogen deprivation and antagonism. The identification of several intracellular pathways promoting resistance to antiestrogen therapy led to the introduction of novel endocrine drug combinations that reformed treatment schema and expanded therapeutic options. There is no doubt that efforts to overcome or delay resistance to ET are fruiting, particularly with the introduction of cyclin-dependent kinase 4/6 inhibitors such as palbociclib and ribociclib, and mechanistic target of rapamycin inhibitors such as everolimus. Although still considered incurable by currently available treatment modalities, many patients with MBC nowadays enjoy several years of good quality life coupled with decent tumor control. The diversity of therapies and unusual pattern of side effects can be quite perplexing to the treating physician. The sequence of variable agents and management of side effects, in addition to the timing of initiation of cytotoxic chemotherapy, is among the challenges faced by oncologists. In this review, we shed a spotlight on mechanisms of resistance to ET, and provide a review of landmark studies that have recently reshaped the landscape of treatment options for patients with metastatic HR-positive, HER2-negative MBC. A suggested treatment strategy for newly diagnosed patients is also discussed herein.
format	article
author	Mohamad Adham Salkeni Samantha June Hall
author_facet	Mohamad Adham Salkeni Samantha June Hall
author_sort	Mohamad Adham Salkeni
title	Metastatic breast cancer: Endocrine therapy landscape reshaped
title_short	Metastatic breast cancer: Endocrine therapy landscape reshaped
title_full	Metastatic breast cancer: Endocrine therapy landscape reshaped
title_fullStr	Metastatic breast cancer: Endocrine therapy landscape reshaped
title_full_unstemmed	Metastatic breast cancer: Endocrine therapy landscape reshaped
title_sort	metastatic breast cancer: endocrine therapy landscape reshaped
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2017
url	https://doaj.org/article/3269b6d99960484c8d2f4b76e075e6f0
work_keys_str_mv	AT mohamadadhamsalkeni metastaticbreastcancerendocrinetherapylandscapereshaped AT samanthajunehall metastaticbreastcancerendocrinetherapylandscapereshaped
_version_	1718384043969478656

Metastatic breast cancer: Endocrine therapy landscape reshaped

Ejemplares similares